A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE).

Nathan Hale Fowler,Ian W. Flinn,Simon Rule,Robert Chen,Long Kwei,Darrin M. Beaupre,Alvina D. Chu,Leo I. Gordon

A multicenter, randomized, double-blind, placebo-controlled phase III study of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab versus placebo in combination with rituximab in patients with treatment-naive follicular lymphoma (PERSPECTIVE).

2017

Nathan Hale Fowler
Ian W. Flinn
Simon Rule
Robert Chen
Long Kwei
Darrin M. Beaupre
Alvina D. Chu
Leo I. Gordon

TPS7576Background: Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. A limited number of chemotherapy-free options exist for patients with treatment-naive (TN) F...

Keywords:

Placebo
Follicular lymphoma
Bruton's tyrosine kinase
Cancer research
Rituximab
Physical therapy
Ibrutinib
Medicine
Oncology
therapy naive
in patient
Lymphoma
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations